Financial PerformanceCibus' revenues increased by 135% year-over-year, mainly through collaboration agreements and sales related to developing a palm oil alternative.
Product DevelopmentThe US FDA completed its Plant Biotechnology Consultation Program for the company’s altered lignin alfalfa trait for livestock feed, enabling the commercialization of the plant.
Regulatory ApprovalsCibus announced that its most recent HT2 trait iteration in Canola was deemed 'not regulated' by USDA-APHIS, increasing the company’s total number of traits designated as such to 17.